Edwards Lifesciences Corporation (NYSE:EW) Stock Has Consensus Price Target of $100.27

Shares of Edwards Lifesciences Corporation (NYSE:EW) have received an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and seventeen have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $100.27.

A number of research analysts recently commented on EW shares. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, September 26th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Piper Sandler restated an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th.

Insider Transactions at Edwards Lifesciences

In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel Lippis sold 619 shares of Edwards Lifesciences stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the transaction, the vice president owned 40,034 shares of the company’s stock, valued at $3,503,375.34. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 5,045 shares of company stock valued at $455,341. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Edwards Lifesciences in the second quarter worth $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $1,274,082,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $803,686,000. Bank of America Corp DE bought a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $605,397,000. Finally, Deutsche Bank AG acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $516,552,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.41 on Friday. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a market capitalization of $49.75 billion, a price-to-earnings ratio of 49.66, a price-to-earnings-growth ratio of 2.31 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm’s fifty day moving average price is $88.58 and its 200 day moving average price is $86.05.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts forecast that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.